Question explored with the scientific record
Ostoporosis infusions
The short version: these infusions increase bone density on a DXA scan, but the evidence for preventing fractures is weaker than most doctors will tell you, and the acute side effects are common and real.
The evidence you are likely to hear quoted comes from the HORIZON trials, which were funded by Novartis, the manufacturer of zoledronic acid (Reclast). The main trial in 7,736 postmenopausal women found that three yearly infusions cut vertebral fractures from about 11% to 3% over three years, and hip fractures from 2.5% to 1.4% [2]. That sounds good, but the absolute numbers matter: about 8 fewer women per 100 had a vertebral fracture, and about 1 fewer per 100 had a hip fracture. The same trial reported 130 deaths in the drug group versus 112 in the placebo group, a difference the authors did not call significant but that is worth noting [2]. A separate review of eight trials found that one of them, by Greenspan, actually showed more vertebral fractures in the treatment group (20% vs 16%) [1]. That is a red flag the summaries tend to skip.
The safety profile is not clean. The acute-phase response is common: about 48% of people getting zoledronate for the first time report flu-like symptoms, myalgia, or fever, compared to 33% with ibandronate [5]. A Turkish study found 19.6% of patients came to the emergency department with these reactions [4]. Headache, fever, and muscle pain are significantly more common than placebo [6]. The atrial fibrillation signal from the big trial (50 vs 20 cases) has never been adequately explained [2]. And the long-term risks—osteonecrosis of the jaw and atypical femur fractures—are real, though rare in osteoporosis populations; the evidence here does not include long-term follow-up beyond three years for most studies [2, 3].
| Outcome | Zoledronic acid | Placebo | Number needed to treat or harm |
|---|---|---|---|
| Vertebral fracture over 3 years | 3.3% | 10.9% | NNT about 13 |
| Hip fracture over 3 years | 1.4% | 2.5% | NNT about 91 |
| Any adverse event | 95.5% | 93.9% | NNH not calculable |
| Acute-phase reaction (first dose) | ~48% | ~33% | NNH about 7 |
| Atrial fibrillation | 50 cases | 20 cases | NNH about 129 |
My call: for a woman with a T-score below -2.5 and a prior fragility fracture, the vertebral fracture reduction is real enough to consider, but the hip fracture benefit is small, the acute reactions are common, and the long-term safety data is thin. For anyone without a prior fracture, the benefit is marginal and the burden of proof has not been met.
Confidence: moderate for vertebral fracture reduction in high-risk women; low for hip fracture benefit and long-term safety.
Sources used 6
-
Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures
A review of eight randomized placebo-controlled trials concluded that bisphosphonate therapy in postmenopausal women with osteoporosis increases bone mineral density and, in four of five fracture-reporting trials, reduces future fracture risk, despite one conflicting trial.
DOI: 10.23880/jobd-16000179 -
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
A multicenter, randomized, double-blind trial in postmenopausal women with osteoporosis showed that annual infusions of zoledronic acid (5 mg) over 3 years significantly reduced vertebral, hip, and other fractures, improved bone density and turnover markers, and had a generally …
DOI: 10.1056/NEJMoa067312 -
Recent Developments in Bisphosphonate Therapy
A comprehensive review of nitrogen-containing bisphosphonates for osteoporosis and glucocorticoid-induced osteoporosis, detailing mechanisms, dosing options (oral and intravenous), clinical trial efficacy on bone density and fracture reduction, safety concerns including gastroin…
DOI: 10.1016/j.semarthrit.2006.12.003 -
Evaluation of intravenous zoledronic acid-induced acute-phase response in the emergency department
A Turkish single-center cross-sectional study found that intravenous zoledronic acid induced acute-phase reactions in about 19% of postmenopausal osteoporotic patients, with diffuse musculoskeletal symptoms being most common and onset time correlating with the number of IV BP do…
DOI: 10.28982/josam.1036910 -
Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate
This study investigates the acute-phase response (APR) in bisphosphonate-naïve and pretreated women with osteoporosis receiving their first intravenous dose of zoledronate or ibandronate, revealing that APR rates and severity differ significantly between the two treatments and a…
DOI: 10.1007/s00198-017-3992-5 -
Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24‐month Clinical Study
This study evaluates the efficacy and safety of intravenous zoledronic acid 5 mg/year in improving bone mineral density and reducing bone turnover markers in East Chinese women with newly diagnosed osteoporosis over a 24-month period.
DOI: 10.1111/os.12307